Cardiac Electrophysiology Review

Editorial: The Future of Cardiac Electrophysiology Review
pp. 311-311(1)
Author: Anderson K.P.

Selection of Pacing Mode after Interruption of Atrioventricular Conduction for Atrial Fibrillation: Observations from the PA³ Clinical Trial
pp. 312-314(3)
Author: Gillis A.M.

Comparison of Permanent Left Ventricular and Biventricular Pacing in Patients with Heart Failure and Chronic Atrial Fibrillation: A Prospective Hemodynamic Study
pp. 315-324(10)
Authors: Garrigue S.; Bordachar P.; Reuter S.; Jaïs P.; Haïssaguerre M.; Clementy J.

Is Bachmann's Bundle the Only Right Site for Single-Site Pacing to Prevent Atrial Fibrillation? Results of a Multicenter Randomized Trial
pp. 325-328(4)
Author: Bailin S.J.

Multisite Atrial Pacing for Atrial Fibrillation Prevention: Where to Go from Here?
pp. 329-332(4)
Authors: Misier A.R.; Beukema W.P.; Willems R.

Detection of Atrial Fibrillation by Permanent Pacemakers: Observations from the STOP AF Trial
pp. 333-340(8)
Authors: Plummer C.J.; McComb J.M.

Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial
pp. 341-344(4)
Authors: Gold M.R.; Leman R.B.; Euler D.E.

Atrial Pacing Therapies for Prevention of Atrial Fibrillation in Patients with Implantable Defibrillators
pp. 345-347(3)
Author: Gillis A.M.

Efficacy of Atrial Antitachycardia Functions for Treating Atrial Fibrillation: Observations in Patients with a Dual-Chamber Defibrillator
pp. 348-351(4)
Authors: Ricci R.; Pignalberi C.; Santini M.

Does Rapid Atrial Pacing Terminate Atrial Fibrillation? A Comparison of Laboratory and Device Termination Studies
pp. 352-354(3)
Authors: Mitchell A.R.J.; Sulke N.

Atrial Arrhythmia Burden as an Endpoint in Clinical Trials: Is it the Best Surrogate? Lessons from a Multicenter Defibrillator Trial
pp. 355-358(4)
Authors: Euler D.E.; Friedman P.A.

Does Sinus Rhythm Beget Sinus Rhythm? Effects of Prompt Cardioversion on the Frequency and Persistence of Recurrent Atrial Fibrillation
pp. 359-365(7)
Authors: Tse H-F.; Lau C-P.

AFFIRM and RACE Trials: Implications for the Management of Atrial Fibrillation
pp. 366-369(4)
Authors: Blackshear J.L.; Safford R.E.

Atrial Fibrillation: Should we Target Platelets or the Coagulation Pathway?
pp. 370-371(2)
Authors: Tan K.T.; Lip G.Y.H.

Aspirin—Anticoagulant Combination in Patients with Non Valvular Atrial Fibrillation Commentary on the FFAACS Study Results
pp. 372-373(2)
Author: Lechat P.P.

Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in
pp. 374-378(5)
Authors: van Walraven C.; Hart R.G.; Singer D.E.; Koudstaal P.J.; Connolly S.

Do Anticoagulation Management Services Improve Care? Implications of the Managing Anticoagulation Services Trial
pp. 379-381(3)
Author: Matchar D.B.

Use of Subcutaneous Enoxaparin Compared to Intravenous Heparin and Oral Phenprocoumon in the Setting of Cardioversion—The ACE Study (Anticoagulation in Cardioversion Using Enoxaparin)
pp. 382-386(5)
Authors: Stellbrink C.; Nixdorff U.; Hofmann T.; Lehmacher W.; Daniel W.G.; Hanrath P.; Geller C.; Mügge A.; Sehnert W.; Schmidt-Lucke C.; Schmidt-Lucke J-A.; on behalf of the ACE Anticoagulation in Cardioversion Using Enoxaparin Study Group

Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation: ACUTE Trial Update
pp. 387-391(5)
Authors: Asher C.R.; Klein A.L.

Cardioversion Related Thromboembolism: Value of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
pp. 392-396(5)
Authors: Seidl K.; Senges J.

Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
pp. 397-400(4)
Authors: Kim M.H.; Trohman R.G.; Eagle K.A.

Relationships between Pacing Mode and Quality of Life: Evidence from Randomized Clinical Trials
pp. 401-405(5)
Author: Newman D.

Selecting the Appropriate Pacing Mode for Patients with Sick Sinus Syndrome: Evidence from Randomized Clinical Trials
pp. 406-410(5)
Authors: Albertsen A.E.; Nielsen J.C.

Second Vasovagal Pacemaker Study (VPS II): Rationale, Design, Results, and Implications for Practice and Future Clinical Trials
pp. 411-415(5)
Authors: Sheldon R.; Connolly S.

Pacing for Vasovagal Syncope After the Second Vasovagal Pacemaker Study (VPS II): A Matter of Judgement
pp. 416-420(5)
Authors: Trim G.M.; Krahn A.D.; Klein G.J.; Skanes A.C.; Yee R.

Cardiac Resynchronization Therapy with or without an Implantable Defibrillator: Only Indicated When Everything Else has Failed?
pp. 421-429(9)
Authors: Ghosh J.; Kaye G.; Cleland J.G.F.

MADIT-II: Substudies and Their Implications
pp. 430-433(4)
Author: Moss A.J.

Risk Stratification for Sudden Death: Do We Need Anything More Than Ejection Fraction?
pp. 434-437(4)
Author: Buxton A.E.

Enhancing Specificity Without Sacrificing Sensitivity: Potential Benefits of Using Microvolt T-Wave Alternans Testing to Risk Stratify the MADIT-II Population
pp. 438-442(5)
Author: Cohen R.J.

Using the MADIT II Criteria for Implantable Cardioverter Defibrillators—What is the Role of the Food and Drug Administration Approval?
pp. 443-446(4)
Author: Barold H.S.

The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims
pp. 447-451(5)
Authors: Grönefeld G.; Connolly S.J.; Hohnloser S.H.; on behalf of the DINAMIT Investigators

Amiodarone versus Implantable Defibrillator (AMIOVIRT): Background, Rationale, Design, Methods, Results and Implications
pp. 452-456(5)
Authors: Wijetunga M.; Strickberger S.A.

DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
pp. 457-462(6)
Authors: Schaechter A.; Kadish A.H.

Clinical Trials of Prophylactic Implantable Defibrillator Therapy in Patients with Nonischemic Cardiomyopathy: What have We Learned and What can We Expect from Future Trials?
pp. 463-467(5)
Author: Grimm W.

The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: Rationale, Design, Results, Clinical Implications and Lessons for Future Trials
pp. 468-472(5)
Authors: Wilkoff B.L.; the DAVID Trial Investigators

Clinical Significance of Device-Related Complications in Clinical Trials and Implications for Future Trials: Insights from the Antiarrhytmics versus Implantable Defibrillators (AVID) Trial
pp. 473-478(6)
Author: Kron J.

Cost-Effectiveness of the Implantable Cardioverter Defibrillator
pp. 479-482(4)
Authors: Hlatky M.A.; Sanders G.D.; Owens D.K.